Estamos no ar no ! Saiba mais

Novo Nordisk

NVO

Valor de mercado US$ 171 bi

38,83 USD

-0,39

0,99%

No fechamento Atualizado 16 de out. 16:00 EDT

Pré-mercado

Após o fechamento do mercado

38,73

-0,10

0,26%

1 dia

-0,99%

5 dias

-0,05%

1 mês

-6,9%

3 meses

-24,57%

6 meses

-5,13%

No acumulado do ano

-25,88%

1 ano

-30,77%

5 anos

-24,92%

10 anos

92,51%

Sobre: With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Funcionários: 69.500

Saúde Fabricantes de medicamentos — geral

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 43%

Neutro 24,7%

Negativo 32,3%

The Motley Fool

Novo Nordisk and Eli Lilly Just Got Some Fantastic News

The study used Novo Nordisk's semaglutide to arrive at its results. The news should only cause the market for GLP-1 drugs to grow faster.

Novo Nordisk and Eli Lilly Just Got Some Fantastic News

Zacks Investment Research

Why Novo Nordisk (NVO) Dipped More Than Broader Market Today

In the latest trading session, Novo Nordisk (NVO) closed at $38.06, marking a -1.35% move from the previous day.

Why Novo Nordisk (NVO) Dipped More Than Broader Market Today

The Motley Fool

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie is aggressively diversifying its pipeline to mitigate the revenue impact from its loss of patent exclusivity on Humira. Novo Nordisk maintains a dominant lead in the rapidly expanding metabolic health market through its blockbuster obesity treatments.

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

Zacks Investment Research

Novo Down 11% in a Month: How Should Investors Approach the Stock Now?

NVO's 11% slide in a month reflects intensifying LLY competition, pricing pressure and a lack of near-term growth visibility despite its long-term pipeline potential.

Novo Down 11% in a Month: How Should Investors Approach the Stock Now?

The Motley Fool

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

Bristol Myers Squibb provides high free cash flow and a deep oncology pipeline at a modest valuation. Novo Nordisk dominates the obesity and diabetes markets with exceptional net margins and steady growth.

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool

UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.

UBS analyst Michael Yee believes investors prefer Eli Lilly's growth story to Novo Nordisk's turnaround story. Yee sees Novo Nordisk turning its business around, but believes it could take some time.

UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.

GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution

Rapid weight loss can lead to issues with bone quality, particularly in older adults.

GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution

Novo Nordisk Vs. Eli Lilly: Judged Against Big Pharma, Only One Needs A Premium

Novo Nordisk is rated Buy versus Hold for Eli Lilly, anchored by a compelling valuation discount to big pharma peers. NVO trades at ~11.2x 2027 earnings, a ~26% discount to peer median, despite consensus growth rates in line with peers and a robust yield. The investment case does not require a rerating; ~10% annual returns are achievable if current discounted valuations hold and yield continues.

Novo Nordisk Vs. Eli Lilly: Judged Against Big Pharma, Only One Needs A Premium

Zacks Investment Research

Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know

Novo Nordisk (NVO) reached $38.26 at the closing of the latest trading day, reflecting a +1.95% change compared to its last close.

Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know

Zacks Investment Research

Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?

Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock growth, but competition and clinical risks loom.

Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™